Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment? - Archive ouverte HAL Access content directly
Journal Articles European Journal of Dermatology Year : 2019

Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?

(1, 2) , (1) , (3, 4) , (4) , (1, 5)
1
2
3
4
5

Abstract

Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]
Not file

Dates and versions

pasteur-03718435 , version 1 (08-07-2022)

Identifiers

Cite

Angelica Tiotiu, Claire Poreaux, Pascal Poncet, Hélène Senechal, J.L. Schmutz. Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?. European Journal of Dermatology, 2019, 29 (1), pp.101-2. ⟨10.1684/ejd.2018.3454⟩. ⟨pasteur-03718435⟩
8 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More